Edgewise Therapeutics Shares Jump After Positive Data On Becker Muscular Dystrophy Study

Edgewise Therapeutics Inc EWTX posted positive topline results from Phase 1b trial of EDG-5506, designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies such as Duchenne muscular dystrophy (DMD) and Becker Muscular Dystrophy (BMD)

  • The seven adults with BMD enrolled in the Phase 1b clinical trial were administered 20 mg oral doses of EDG-5506 (n=5) or placebo (n=2). 
  • EDG-5506 was shown to be well-tolerated with no discontinuations or dose reductions. 
  • Related: Edgewise Therapeutics Posts Data From Early-Stage Muscle Wasting Disease Trial.
  • The most common adverse event observed in all Phase 1b participants, was dizziness which was mild, transient, and self-resolving.
  • Similar to observations in the healthy volunteer portion of the clinical trial, dosing with EDG-5506 did not affect voluntary grip, shoulder, or hip strength.
  • Treatment with EDG-5506 led to a significant and time-dependent decrease in key biomarkers of muscle damage.
  • Price Action: EWTX shares are up 20.10% at $18.60 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsPhase 1 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!